Capricor Therapeutics (CAPR) Misses Q2 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/8/2026

1. LEVI
2. NVDA
3. SBUX
4. SPY
5. GOOGL
6. APLD
7. USO
8. STZ
9. AGNT
10. ORCL

Go back to Capricor Therapeutics (CAPR) Misses Q2 EPS by 2c

Capricor Therapeutics Reports Second Quarter 2016 Financial Results and Provides Clinical Update

August 15, 2016 4:05 PM EDT

LOS ANGELES, Aug. 15, 2016 /PRNewswire/ -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today provided an update on its clinical development programs directed toward the treatment of heart disease, including that associated with Duchenne Muscular Dystrophy (DMD), as well as defined the initial development path for its proprietary exosomes technology. Capricor also announced financial results for the quarter ended June 30, 2016.

Linda Marbán, Ph.D.,... More